Lipella Pharmaceuticals Inc. LIPO
At closeNov 2, 2026, 4:00 PM EST
After hours · Nov 2, 4:00 PM ET
- YTD
- -99.67%
- 1 year
- -99.86%
- Market cap
- 2.77K
- Revenue (ttm)
- 507.20K
- EPS (ttm)
- -2.26
- Shares out
- 1.21M
- Forward P/E
- -0.97
- YTD return
- -99.67%
- 1-year return
- -99.86%
- Volume
- 160.09K
- Avg volume
- 910
- Open
- 0.058
- Previous close
- 0.0006
- Day's range
- 0.0327 – 0.058
- 52-week range
- 0.0002 – 0.54
- Price target
- 10.00 (+1666566.7%)
- Earnings date
- Feb 27, 2024
2Y -2.7194 (-99.98%)
Key statistics
- Enterprise value
- 1.34M
- PEG ratio
- 0.00
- Price / sales
- 7.39
- Price / book
- 0.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.90%
- Free cash flow
- -2.25M
- Total cash
- 1.19M
- Total debt
- 93.68K
- Return on equity
- -171.56%
- Short % of float
- 0.26%
- 50-day average
- 2.98
- 200-day average
- 4.27
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 27, 2024
Expected Feb 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.29 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.96 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.28 | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -1.84 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -2.16 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 9, 2024 | Maxim Group | init | — | Buy |
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lipella.com
News
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11 
Lipella Pharmaceuticals (NASDAQ:LIPO) Trading Down 14.8% – Here’s What Happened 
Lipella Pharmaceuticals (NASDAQ:LIPO) Stock Price Up 4.2% – Still a Buy? 
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting 
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market 
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology 
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development 
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
Your note
Sign in to keep a note on LIPO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANCELLOR MICHAEL B. | Officer, Director and Beneficial Owner | Stock Award(Grant) | Mar 12, 2024 | 877,637 |
| KAUFMAN JONATHAN | Chief Executive Officer | Purchase | May 13, 2024 | 898,849 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 0.36% | 4,315 | 13.38K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.26% | 3,114 | 9.65K | Sep 29, 2024 |
| HRT Financial LP | 0.18% | 2,202 | 6.83K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 962 | 2.98K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 6 | 18 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.36% | 4,315 | 13.38K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 3,057 | 9.48K | Oct 30, 2024 |